Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II BEZ235 monotherapy in malignant PEComa
NL-OMON37195Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dactolisib in Perivascular epithelioid cell neoplasm (PEComa), sponsored by Novartis. Primary endpoint: Objective response according to RECIST 1.1. Started Oct 2012; status: active, not recruiting.
02
Drugs
dactolisib
03
Conditions
Perivascular epithelioid cell neoplasm (PEComa)
Beyond the preview
Go deeper on NL-OMON37195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37195.